Toshiya Fujisaki

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Kazuhiro Sato, Hiroshi Tanaka, Aya Ohtsubo, 2021, Frontiers in Oncology.

PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer

Miyuki Sato, Aya Ohtsubo, Kosuke Ichikawa, 2021, Cancer Immunology, Immunotherapy.

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease

Kazuhiro Sato, Hiroshi Tanaka, Aya Ohtsubo, 2021, Translational lung cancer research.

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

K. Nishio, Daisuke Ishikawa, T. Sekiya, 2022, Cancers.

Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review

G. Hasegawa, Y. Yoneoka, T. Takada, 2017, Internal medicine.

The prolyl hydroxylase OGFOD1 promotes cancer cell proliferation by regulating the expression of cell cycle regulators

E. Kondo, Ken Saito, T. Kikuchi, 2022, FEBS letters.

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients

Aya Ohtsubo, Kosuke Ichikawa, T. Kikuchi, 2021, Translational lung cancer research.